Balloon (Foley or ATAD) vs low‐dose vaginal misoprostol
Balloon (Foley or ATAD) may leads to higher caesarean section compared with low‐dose vaginal misoprostol (low certainty).
- RR 1.28 [1.02, 1.6]12 studies · 1756 participantsLow
Balloon (Foley or ATAD) may leads to higher caesarean section compared with low‐dose vaginal misoprostol (low certainty).
It is very uncertain whether balloon (Foley or ATAD) changes serious neonatal morbidity or perinatal death compared with low‐dose vaginal misoprostol (very low certainty).
Balloon (Foley or ATAD) showed no clear difference in apgar score < 7 at 5 minutes compared with low‐dose vaginal misoprostol (low certainty).
Balloon (Foley or ATAD) showed no clear difference in neonatal intensive care unit admission compared with low‐dose vaginal misoprostol (low certainty).
Balloon (Foley or ATAD) probably leads to higher vaginal delivery not achieved within 24 hours compared with low‐dose oral misoprostol (moderate certainty).
Balloon (Foley or ATAD) showed no clear difference in uterine hyperstimulation with FHR changes compared with low‐dose oral misoprostol (low certainty).
Balloon (Foley or ATAD) probably leads to higher caesarean section compared with low‐dose oral misoprostol (moderate certainty).
Balloon (Foley or ATAD) showed no clear difference in serious neonatal morbidity or perinatal death compared with low‐dose oral misoprostol (low certainty).
It is very uncertain whether balloon (Foley or ATAD) changes serious maternal morbidity or death compared with low‐dose oral misoprostol (very low certainty).
Balloon (Foley or ATAD) showed no clear difference in apgar score < 7 after 5 minutes compared with low‐dose oral misoprostol (low certainty).
Balloon (Foley or ATAD) showed no clear difference in neonatal intensive care unit admission compared with low‐dose oral misoprostol (low certainty).
Balloon (Foley or ATAD) showed no clear difference in vaginal delivery not achieved in 24 hours compared with low‐dose vaginal misoprostol (low certainty).
Balloon (Foley or ATAD) probably leads to lower uterine hyperstimulation with FHR changes compared with low‐dose vaginal misoprostol (moderate certainty).